

Supporting Information

Pillar[5]arene-Derived *endo*-Functionalized Molecular Tube for Mimicking Protein-Ligand Interactions

Zhuo Wang^{1,2,3}, Tao Chen^{1,2}, Hua Liu³, Yahu A. Liu⁴, Xiao-Li Zhao⁵,
Wei-Bo Hu^{*,1}, Hui Yang^{*,1,3} and Ke Wen^{*,1,3}

¹Shanghai Advanced Research Institute, Chinese Academy of Sciences,
Shanghai 201210, China

²University of Chinese Academy of Sciences, Beijing 100049, China

³School of Physical Science and Technology, ShanghaiTech University,
Shanghai 201210, China

⁴Medicinal Chemistry, ChemBridge Research Laboratories,
San Diego, CA 92127, USA

⁵Shanghai Key Laboratory of Green Chemistry and Chemical Processes,
Department of Chemistry, East China Normal University, Shanghai 200062, China.

*Corresponding Authors

Wei-Bo Hu, PhD
E-Mail: huwb@sari.ac.cn

Hui Yang, PhD
E-Mail: yangh@sari.ac.cn

Ke Wen, PhD
E-Mail: wenk@sari.ac.cn

Table of Contents

Methods and Synthetic Procedures

General	S10
Synthesis of [P4-(OH)BPO]	S10
NMR experiments	S11
Figure S1 Structure of [P4-(OH)BPO]	S11
Calculations	S11
Figure S2 ^1H NMR of [P4-(OH)BPO] in CD_2Cl_2	S12
Figure S3 ^{13}C NMR of [P4-(OH)BPO] in CD_2Cl_2	S12
Figure S4 HRMS spectrum of [P4-(OH)BPO]	S13
Figure S5 Partial ^1H NMR of [P4-(OH)BPO] in deuterated solvents	S13

NMR Spectra of **[P4-(OH)BPO]**–Guest Complexation

Figure S6 ^1H NMR spectra of 1 , [P4-(OH)BPO] and mixture of 1 and [P4-(OH)BPO]	S14
Figure S7 ^1H NMR spectra of 2 , [P4-(OH)BPO] and mixture of 2 and [P4-(OH)BPO]	S14
Figure S8 ^1H NMR spectra of 3 , [P4-(OH)BPO] and mixture of 3 and [P4-(OH)BPO]	S15
Figure S9 ^1H NMR spectra of 4 , [P4-(OH)BPO] and mixture of 4 and [P4-(OH)BPO]	S15
Figure S10 ^1H NMR spectra of 5 , [P4-(OH)BPO] and mixture of 5 and [P4-(OH)BPO]	S16
Figure S11 ^1H NMR spectra of 6 , [P4-(OH)BPO] and mixture of 6 and [P4-(OH)BPO]	S16
Figure S12 ^1H NMR spectra of 7 , [P4-(OH)BPO] and mixture of 7 and [P4-(OH)BPO]	S17
Figure S13 ^1H NMR spectra of 8 , [P4-(OH)BPO] and mixture of 8 and [P4-(OH)BPO]	S17
Figure S14 ^1H NMR spectra of 9 , [P4-(OH)BPO] and mixture of 9 and [P4-(OH)BPO]	S18
Figure S15 ^1H NMR spectra of 10 , [P4-(OH)BPO] and mixture of 10 and [P4-(OH)BPO]	S18
Figure S16 ^1H NMR spectra of 11 , [P4-(OH)BPO] and mixture of 11 and [P4-(OH)BPO]	S19
Figure S17 ^1H NMR spectra of 12 , [P4-(OH)BPO] and mixture of 12 and [P4-(OH)BPO]	S19
Figure S18 ACPI-MS spectrum of 13c [P4-(OH)BPO]	S20
Figure S19 ^1H NMR spectra of 13 , [P4-(OH)BPO] and mixture of 13 and [P4-(OH)BPO]	S20
Figure S20 ^1H NMR spectra of 14 , [P4-(OH)BPO] and mixture of 14 and [P4-(OH)BPO]	S21
Figure S21 ^1H NMR spectra of 15 , [P4-(OH)BPO] and mixture of 15 and [P4-(OH)BPO]	S21
Figure S22 ^1H NMR spectra of 16 , [P4-(OH)BPO] and mixture of 16 and [P4-(OH)BPO]	S22
Figure S23 ^1H NMR spectra of 17 , [P4-(OH)BPO] and mixture of 17 and [P4-(OH)BPO]	S22
Figure S24 ^1H NMR spectra of 18 , [P4-(OH)BPO] and mixture of 18 and [P4-(OH)BPO]	S23
Figure S25 ^1H NMR spectra of 19 , [P4-(OH)BPO] and mixture of 19 and [P4-(OH)BPO]	S23

Figure S26	^1H NMR spectra of 20 , [P4-(OH)BPO] and mixture of 20 and [P4-(OH)BPO]	S24
Figure S27	^1H NMR spectra of 21 , [P4-(OH)BPO] and mixture of 21 and [P4-(OH)BPO]	S24
Figure S28	^1H NMR spectra of 22 , [P4-(OH)BPO] and mixture of 22 and [P4-(OH)BPO]	S25
Figure S29	^1H NMR spectra of 23 , [P4-(OH)BPO] and mixture of 23 and [P4-(OH)BPO]	S25
Figure S30	^1H NMR spectra of 24 , [P4-(OH)BPO] and mixture of 24 and [P4-(OH)BPO]	S26
Figure S31	^1H NMR spectra of 25 , [P4-(OH)BPO] and mixture of 25 and [P4-(OH)BPO]	S26
Figure S32	^1H NMR spectra of 26 , [P4-(OH)BPO] and mixture of 26 and [P4-(OH)BPO]	S27
Figure S33	^1H NMR spectra of 27 , [P4-(OH)BPO] and mixture of 27 and [P4-(OH)BPO]	S27
Figure S34	^1H NMR spectra of 28 , [P4-(OH)BPO] and mixture of 28 and [P4-(OH)BPO]	S28
Figure S35	^1H NMR spectra of 29 , [P4-(OH)BPO] and mixture of 29 and [P4-(OH)BPO]	S28
Figure S36	^1H NMR spectra of 30 , [P4-(OH)BPO] and mixture of 30 and [P4-(OH)BPO]	S29
Figure S37	^1H NMR spectra of 31 , [P4-(OH)BPO] and mixture of 31 and [P4-(OH)BPO]	S29
Figure S38	^1H NMR spectra of 32 , [P4-(OH)BPO] and mixture of 32 and [P4-(OH)BPO]	S30
Figure S39	^1H NMR spectra of 33 , [P4-(OH)BPO] and mixture of 33 and [P4-(OH)BPO]	S30
Figure S40	^1H NMR spectra of 34 , [P4-(OH)BPO] and mixture of 34 and [P4-(OH)BPO]	S31
Figure S41	^1H NMR spectra of 35 , [P4-(OH)BPO] and mixture of 35 and [P4-(OH)BPO]	S31
Figure S42	^1H NMR spectra of 36 , [P4-(OH)BPO] and mixture of 36 and [P4-(OH)BPO]	S32
Figure S43	^1H NMR spectra of 37 , [P4-(OH)BPO] and mixture of 37 and [P4-(OH)BPO]	S32
Figure S44	^1H NMR spectra of 38 , [P4-(OH)BPO] and mixture of 38 and [P4-(OH)BPO]	S33
Figure S45	^1H NMR spectra of 39 , [P4-(OH)BPO] and mixture of 39 and [P4-(OH)BPO]	S33
Figure S46	^1H NMR spectra of 40 , [P4-(OH)BPO] and mixture of 40 and [P4-(OH)BPO]	S34
Figure S47	^1H NMR spectra of hexane, [P4-(OH)BPO] and mixture of hexane and [P4-(OH)BPO]	S34

Job Plots Deriving from a 1:1 Complexation of *endo*-[P4-BPO(1-OH)] and Guests

Figure S48	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 1	S35
Figure S49	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 2	S35
Figure S50	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 3	S36
Figure S51	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 4	S36
Figure S52	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 5	S37
Figure S53	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 6	S37
Figure S54	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 7	S38
Figure S55	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 8	S38
Figure S56	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 9	S39
Figure S57	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 10	S39
Figure S58	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 11	S40
Figure S59	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 12	S40

Figure S60	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 13	S41
Figure S61	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 14	S41
Figure S62	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 15	S42
Figure S63	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 16	S42
Figure S64	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 17	S43
Figure S65	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 18	S43
Figure S66	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 19	S44
Figure S67	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 20	S44
Figure S68	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 21	S45
Figure S69	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 22	S45
Figure S70	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 23	S46
Figure S71	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 24	S46
Figure S72	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 25	S47
Figure S73	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 26	S47
Figure S74	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 27	S48
Figure S75	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 28	S48
Figure S76	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 29	S49
Figure S77	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 30	S49
Figure S78	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 31	S50
Figure S79	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 32	S50
Figure S80	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 33	S51
Figure S81	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 34	S51
Figure S82	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 35	S52
Figure S83	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 36	S52
Figure S84	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 37	S53
Figure S85	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 38	S53
Figure S86	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 39	S54
Figure S87	Job plot deriving from a 1:1 complexation of <i>endo</i> -[P4-BPO(1-OH)] and 40	S54

Nonlinear Curve Fitting of NMR Titrations

Figure S88	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 1 at varying molar concentrations	S55
Figure S89	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 1	S55
Figure S90	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 2 at varying molar concentrations	S56
Figure S91	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 2	S56

Figure S92	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 3 at varying molar concentrations	S57
Figure S93	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 3	S57
Figure S94	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 4 at varying molar concentrations	S58
Figure S95	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 4	S58
Figure S96	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 5 at varying molar concentrations	S59
Figure S97	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 5	S59
Figure S98	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 6 at varying molar concentrations	S60
Figure S99	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 6	S60
Figure S100	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 7 at varying molar concentrations	S61
Figure S101	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 7	S61
Figure S102	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 8 at varying molar concentrations	S62
Figure S103	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 8	S62
Figure S104	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 9 at varying molar concentrations	S63
Figure S105	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 9	S63
Figure S106	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 10 at varying molar concentrations	S64
Figure S107	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 10	S64
Figure S108	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 11 at varying molar concentrations	S65
Figure S109	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 11	S65
Figure S110	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 12 at varying molar concentrations	S66
Figure S111	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 12	S66
Figure S112	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 13 at varying molar concentrations	S67

Figure S113	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 13	S67
Figure S114	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 14 at varying molar concentrations	S68
Figure S115	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 14	S68
Figure S116	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 15 at varying molar concentrations	S69
Figure S117	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 15	S69
Figure S118	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 16 at varying molar concentrations	S70
Figure S119	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 16	S70
Figure S120	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 17 at varying molar concentrations	S71
Figure S121	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 17	S71
Figure S122	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 18 at varying molar concentrations	S72
Figure S123	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 18	S72
Figure S124	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 19 at varying molar concentrations	S73
Figure S125	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 19	S73
Figure S126	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 20 at varying molar concentrations	S74
Figure S127	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 20	S74
Figure S128	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 21 at varying molar concentrations	S75
Figure S129	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 21	S75
Figure S130	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 22 at varying molar concentrations	S76
Figure S131	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 22	S76
Figure S132	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 23 at varying molar concentrations	S77
Figure S133	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 23	S77

Figure S134	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 24 at varying molar concentrations	S78
Figure S135	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 24	S78
Figure S136	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 25 at varying molar concentrations	S79
Figure S137	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 25	S79
Figure S138	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 26 at varying molar concentrations	S80
Figure S139	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 26	S80
Figure S140	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 27 at varying molar concentrations	S81
Figure S141	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 28 at varying molar concentrations	S81
Figure S142	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 29 at varying molar concentrations	S82
Figure S143	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 29	S82
Figure S144	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 30 at varying molar concentrations	S83
Figure S145	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 30	S83
Figure S146	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 31 at varying molar concentrations	S84
Figure S147	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 31	S84
Figure S148	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 32 at varying molar concentrations	S85
Figure S149	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 32	S85
Figure S150	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 33 at varying molar concentrations	S86
Figure S151	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 33	S86
Figure S152	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 34 at varying molar concentrations	S87
Figure S153	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 34	S87
Figure S154	Partial ^1H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 35 at varying molar concentrations	S88

Figure S155	The nonlinear curve fitting NMR titration for the complexation of [P4-(OH)BPO] with 35	S88
Figure S156	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 36 at varying molar concentrations	S89
Figure S157	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 36	S89
Figure S158	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 37 at varying molar concentrations	S90
Figure S159	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 37	S90
Figure S160	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 38 at varying molar concentrations	S91
Figure S161	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 38	S91
Figure S162	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 39 at varying molar concentrations	S92
Figure S163	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 39	S92
Figure S164	Partial ¹ H NMR spectra of a mixture of [P4-(OH)BPO] (10.0 mM) and 40 at varying molar concentrations	S93
Figure S165	The nonlinear curve fitting of NMR titration for the complexation of [P4-(OH)BPO] with 40	S93

2D NOSEY Spectra

Figure S166	Partial 2D NOESY spectrum of the mixture of [P4-(OH)BPO] and 1	S94
Figure S167	Partial 2D NOESY spectrum of the mixture of [P4-(OH)BPO] and 4	S94
Figure S168	Partial 2D NOESY spectrum of the mixture of [P4-(OH)BPO] and 7	S95
Figure S169	Partial 2D NOESY spectrum of the mixture of [P4-(OH)BPO] and 10	S95
Figure S170	Partial 2D NOESY spectrum of the mixture of [P4-(OH)BPO] and 13	S96
Figure S171	Partial 2D NOESY spectrum of the mixture of [P4-(OH)BPO] and 25	S96
Figure S172	Partial 2D NOESY spectrum of the mixture of [P4-(OH)BPO] and 29	S97
Figure S173	Partial 2D NOESY spectrum of the mixture of [P4-(OH)BPO] and 39	S97
Figure S174	Partial 2D NOESY spectrum of the mixture of [P4-(OH)BPO] and 40	S98
Figure S175	Partial 2D NOESY spectrum of the mixture of [P4-(OH)BPO] and hexane	S98

Single-Crystal X-ray Crystallography

Crystallographic Data of acetone- <i>endo</i> -[P4-(OH)BPO]	S99
Crystallographic Data of 9 - <i>endo</i> -[P4-(OH)BPO]	S100

Crystallographic Data of 13 <i>cendo</i> -[P4-(OH)BPO]	S101
Crystallographic Data of 17 <i>cendo</i> -[P4-(OH)BPO]	S102
Crystallographic Data of 21 <i>cendo</i> -[P4-(OH)BPO]	S103
Crystallographic Data of 24 <i>cendo</i> -[P4-(OH)BPO]	S104
Crystallographic Data of 25 <i>cendo</i> -[P4-(OH)BPO]	S105
Crystallographic Data of 31 <i>cendo</i> -[P4-(OH)BPO]	S106
Crystallographic Data of 36 <i>cendo</i> -[P4-(OH)BPO]	S107
Crystallographic Data of hexane <i>cexo</i> -[P4-(OH)BPO]	S108

Calculation of Mulliken charges

Calculated Mulliken charges for the atoms in 21	S109
Calculated Mulliken charges for the atoms in 24	S110
Calculated Mulliken charges for the atoms in 25	S111


References	S112
-------------------	------

Methods and Synthetic Procedures

General

Unless otherwise noted, all commercial reagents and solvents were used without purification. Separation by flash column chromatography was performed on silica gel (200-300 mesh). ¹H and ¹³C NMR spectra were recorded on Bruker AVANCE NEO 400 NMR spectrometer in CDCl₃ at 298K. Atmospheric pressure chemical ionization (APCI) mass spectra were recorded on a Thermo Scientific Q Exactive Focus (UltiMate 3000 HPLC) mass spectrometer. Single crystal X-ray diffraction data were collected at 100 K on a Rigaku-Oxford Diffraction SuperNova dual source diffractometer (Cu at Zero equipped with an AtlasS2 CCD using Cu K α radiation). The data were collected and processed using CrysAlisPro. The structures were solved by direct methods using Olex2 software, and the non-hydrogen atoms were refined anisotropically with SHELXL-2018 using a full-matrix least-squares procedure based on F^2 . The weighted R factor, wR and goodness-of-fit S values were obtained based on F^2 . The hydrogen atom positions were fixed geometrically at the calculated distances and allowed to ride on their parent atoms. Crystallographic data for the structures disclosed in this paper have been deposited at the Cambridge Crystallographic Data Center (CCDC).

Synthesis of [P4-(OH)BPO]



To a solution of **P4Q**^{S1} (1.44 g, 2 mmol) in THF (200 mL) was added a solution of phenyllithium in ether (2.0 mL, 1.0 M) at -78 °C under nitrogen. The resulting mixture which was warmed to 0 °C, and stirred at 0 °C for 2 h, and poured into saturated NH₄Cl solution (300 mL). The aqueous phase was extracted with EtOAc (3 × 100 mL). The combined organic extracts were concentrated under reduced pressure to result in a residue which was subjected to column chromatography to afford **[P4-(OH)BPO]** as white solid (1.44 g, 90%). ¹H NMR (400 MHz, CD₂Cl₂, 298K) δ 7.57 (s, 1H), 7.46 (t, 2H), 7.39 (s, 1H), 7.31 (d, 2H), 6.99 (d, 2H), 6.98 (s, 1H), 6.93 (s, 2H), 6.91 (t, 3H), 6.74 (s, 1H), 6.65 (s, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.81 (t, 14H), 3.77 (s, 3H), 3.74 (s, 3H), 3.73 (s, 3H), 3.68 (s, 2H), 3.55 (s, 3H); ¹³C NMR (400 MHz, CD₂Cl₂, 298K) δ 152.1, 151.9, 151.0, 150.8, 150.7, 148.9, 148.6, 148.1, 144.7, 139.4, 129.7, 129.2, 128.9, 128.8, 128.4, 128.3, 128.0, 127.9, 127.3, 127.0, 125.0, 56.9, 56.7, 56.1, 55.9, 31.3, 30.1, 29.6, 29.3, 25.6. APCI-MS (ESI): calcd for C₄₉H₅₀O₁₀ [M+NH₄⁺] m/z 798.3404, found 796.4582.

NMR experiments

All ^1H NMR spectra were recorded at a Bruker Avance III HD 400 MHz spectrometer. ^1H NMR experiments were performed on all of the host–guest pairs at a 1:1 ratio, and the peak shifts of the complexed host and guest relative to the free species were used to access complexation. Job plots^{S2} showing the 1:1 stoichiometry of the complex between **[P4-(OH)BPO]** and **G** ($\text{G} = 1\text{--}42$) in CDCl_3 were obtained by plotting the chemical shift ($\Delta\delta$) of the guest's proton in ^1H NMR spectra against the mole fraction of complex ($[\text{host}] + [\text{guest}] = 20.0 \text{ mM}$). In the determination of binding constants of complexes **G** \subset **[P4-(OH)BPO]** ($\text{G} = 1\text{--}41$), ^1H NMR titrations were performed in CDCl_3 with the host concentration of 10.0 mM and varying concentrations of the guest (0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM)^{S3}. The nonlinear curve fitting was calculated by the following equation:

$$\Delta\delta = (\Delta\delta_\infty/[\text{host}]_0) (0.5[\text{guest}]_0 + 0.5([\text{host}]_0 + 1/K_a) - (0.5([\text{guest}]_0^2 + 2[\text{guest}]_0(1/K_a - [\text{host}]_0)) + (1/K_a + [\text{host}]_0)^2)^{0.5}))$$

Where $\Delta\delta$ is the chemical shift change of H_α (Figure S1) of the host at the total concentration of the guest $[\text{guest}]_0$, $\Delta\delta_\infty$ is the chemical shift change of H_α when host is completely complexed, $[\text{host}]_0$ is the fixed initial concentration of the host, and $[\text{guest}]_0$ is the varying total concentration of the guest.




Figure S1. Structure of **[P4-(OH)BPO]**.

Calculations

Quantum chemical calculations were performed using Gaussian 16^{S4}. Fragment library compounds and designed “drug molecules” were calculated by RMO62X 6-311G (d,p) level of theory, and vibrational frequency calculations have been carried out to verify that all optimized geometries are true minima. Molecular volume (V) and surface area (S) of guest molecules were calculated using Marching Tetrahedron algorithm via Multiwfn program^{S5}. Dipole moment values were calculated using Gaussian 09 at the RB3LYP/6-31++G level of calculation.

Asphericity (Ω_a) was defined as $\Omega_a = \frac{(I_A - I_B)^2 + (I_A - I_C)^2 + (I_B - I_C)^2}{2(I_A + I_B + I_C)^2}$, I_A , I_B and I_C are the principal moments of inertia of a molecule^{S6}. Mulliken charges were calculated by Gaussian 09 at PM6-D3 level. Molecular docking of **G** \subset **[P4-(OH)BPO]** ($\text{G} = 39$ or 40) was performed with AutoDock Vina^{S7}.




Figure S2. ^1H NMR of [P4-(OH)BPO] in CD_2Cl_2 .




Figure S3. ^{13}C NMR of [P4-(OH)BPO] in CD_2Cl_2 .

NMR Spectra of [P4-(OH)BPO]–Guest Complexation




Figure S6. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-butylamine (**1**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **1** and [P4-(OH)BPO].




Figure S7. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-hexylamine (**2**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **2** and [P4-(OH)BPO].




Figure S8. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-octylamine (**3**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **3** and [P4-(OH)BPO].




Figure S9. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-butanol (**4**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **4** and [P4-(OH)BPO].




Figure 10. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-hexanol (**5**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **5** and [P4-(OH)BPO].




Figure 11. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-octanol (**6**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **6** and [P4-(OH)BPO].




Figure S12. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-butyaldehyde (7), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of 7 and [P4-(OH)BPO].




Figure S13. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-hexanaldehyde (8), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of 8 and [P4-(OH)BPO].




Figure S14. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-octanaldehyde (**9**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **9** and [P4-(OH)BPO].




Figure S15. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of methyl butyrate (**10**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **10** and [P4-(OH)BPO].




Figure S16. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of methyl hexanoate (**11**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **11** and [P4-(OH)BPO].




Figure S17. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of methyl octanoate (**12**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **12** and [P4-(OH)BPO].




Figure S18. APCI-MS spectrum of **13c-[P4-(OH)BPO]**




Figure S19. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-butanoic acid (**13**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **13** and [P4-(OH)BPO].




Figure S20. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-hexanoic acid (**14**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **14** and [P4-(OH)BPO].




Figure S21. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *n*-octanoic acid (**15**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **15** and [P4-(OH)BPO].




Figure S22. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-methylformamide (**16**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **16** and [P4-(OH)BPO].




Figure S23. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N,N*-dimethylformamide (**17**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **17** and [P4-(OH)BPO].




Figure S24. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-ethylformamide (**18**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **18** and [P4-(OH)BPO].




Figure S25. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-octylformamide (**19**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **19** and [P4-(OH)BPO].




Figure S26. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-methylacetamide (**20**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **20** and [P4-(OH)BPO].




Figure S27. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-ethylacetamide (**21**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **21** and [P4-(OH)BPO].




Figure S28. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-propylacetamide (**22**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **22** and [P4-(OH)BPO].




Figure S29. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-butylacetamide (**23**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **23** and [P4-(OH)BPO].




Figure S30. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-methylpropionamide (24), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of 24 and [P4-(OH)BPO].




Figure 31. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-butylpentanamide (25), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of 25 and [P4-(OH)BPO].




Figure S32. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-methyl pyrrolidone (**26**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **26** and [P4-(OH)BPO].




Figure S33. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of tetrahydrofuran (**27**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **27** and [P4-(OH)BPO].




Figure S34. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of pyrole (28), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of 28 and [P4-(OH)BPO].




Figure S35. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of imidazole (29), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of 29 and [P4-(OH)BPO].




Figure S36. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of oxazole (**30**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **30** and [P4-(OH)BPO].




Figure S37. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of thiazole (**31**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **31** and [P4-(OH)BPO].




Figure S38. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of 4-methylthiazole (32), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of 32 and [P4-(OH)BPO].




Figure S39. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of 3,5-dimethylisoxazole (33), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of 33 and [P4-(OH)BPO].




Figure S40. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of 1-butylimidazole (**34**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **34** and [P4-(OH)BPO].




Figure S41. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of dimethylsulfoxide (**35**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **35** and [P4-(OH)BPO].




Figure S42. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of 1-nitropropane (**36**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **36** and [P4-(OH)BPO].




Figure S43. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of acetonitrile (**37**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **37** and [P4-(OH)BPO].




Figure S44. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of 2-butyloxirane (**38**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **38** and [P4-(OH)BPO].




Figure S45. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-(3-hydroxypropyl)acetamide (**39**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **39** and [P4-(OH)BPO].




Figure S46. ¹H NMR spectra (400 MHz, CDCl₃, 298 K) of *N*-(3-hydroxypropyl)formamide (**40**), [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of **40** and [P4-(OH)BPO].




Figure S47. ¹H NMR spectra (400 MHz, CDCl₃ 298 K) of hexane, [P4-(OH)BPO] (10.0 mM), and an equimolar mixture of hexane and [P4-(OH)BPO].

Job Plots Deriving from a 1:1 Complexation of *endo*-[P4-BPO(1-OH)] and Guests




Figure S48. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-butylamine (**1**).




Figure S49. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-hexylamine (**2**).




Figure S50. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-octylamine (**3**).




Figure S51. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-butanol (**4**).




Figure S52. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-hexanol (**5**).




Figure S53. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-octanol (**6**).




Figure S54. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-butyrальdehyde (7).




Figure S55. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-hexanaldehyde (8).




Figure S56. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-octanaldehyde (**9**).




Figure S57. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and methyl butyrate (**10**).




Figure S58. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and methyl hexanoate (**11**).




Figure S59. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and methyl octanoate (**12**).




Figure S60. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-butanoic acid (13).




Figure S61. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-hexanoic acid (14).




Figure S62. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *n*-butanoic acid (**15**).




Figure S63. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-methylformamide (**16**).




Figure S64. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N,N*-dimethylformamide (**17**).




Figure S65. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-ethylformamide (**18**).




Figure S66. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-octylformamide (**19**).




Figure S67. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-methylacetamide (**20**).




Figure S68. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-ethylacetamide (**21**).




Figure S69. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-propylacetamide (**22**).




Figure S70. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-butylacetamide (23).




Figure S71. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-methylpropionamide (24).




Figure S72. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-butylpentanamide (25).




Figure S73 Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-methyl pyrrolidone (26).




Figure S74. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and tetrahydrofuran (27).




Figure S75. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and pyrole (28).




Figure S76. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and imidazole (**29**).




Figure S77. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and oxazole (**30**).




Figure S78. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and thiazole (31).




Figure S79. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and 4-methylthiazole (32).




Figure S80. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and 3,5-dimethylisoxazole (33).




Figure S81. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and 1-butyylimidazole (34).




Figure S82. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and dimethylsulfoxide (**35**).




Figure S83. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and 1-nitropropane (**36**).




Figure S84. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and acetonitrile (37).




Figure S85. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and 2-butyloxirane (38).




Figure S86. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-(3-hydroxypropyl)acetamide (**39**).




Figure S87. Job plot showing a 1:1 binding stoichiometry between *endo*-[P4-BPO(1-OH)] and *N*-(3-hydroxypropyl)formamide (**40**).

Nonlinear Curve Fitting of NMR Titrations




Figure S88. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and n -butylamine (**1**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S89. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with n -butylamine (**1**) in CDCl_3 at 298 K.




Figure S90. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-hexylamine (**2**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S91. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-hexylamine (**2**) in CDCl_3 at 298 K.




Figure S92. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-octylamine (**3**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S93. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-octylamine (**3**) in CDCl_3 at 298 K.




Figure S94. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-butanol (**4**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S95. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-butanol (**4**) in CDCl_3 at 298 K.




Figure S96. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-hexanol (**5**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S97. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-hexanol (**5**) in CDCl_3 at 298 K.




Figure S98. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-octanol (**6**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S99. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-octanol (**6**) in CDCl_3 at 298 K.




Figure S100. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-butylaldehyde (**7**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S101. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-butylaldehyde (**7**) in CDCl_3 at 298 K.




Figure S102. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-hexanaldehyde (**8**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S103. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-hexanaldehyde (**8**) in CDCl_3 at 298 K.




Figure S104. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-octanaldehyde (**9**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S105. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-octanaldehyde (**9**) in CDCl_3 at 298 K.




Figure S106. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and methyl butyrate (**10**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S107. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with methyl butyrate (**10**) in CDCl_3 at 298 K.




Figure S108. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and methyl hexanoate (**11**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S109. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with methyl hexanoate (**11**) in CDCl_3 at 298 K.




Figure S110. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and methyl octanoate (**12**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S111. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with methyl octanoate (**12**) in CDCl_3 at 298 K.




Figure S112. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-butanoic acid (**13**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S113. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-butanoic acid (**13**) in CDCl_3 at 298 K.




Figure S114. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-hexanoic acid (**14**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S115. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-hexanoic acid (**14**) in CDCl_3 at 298 K.




Figure S116. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *n*-octanoic acid (**15**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S117. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *n*-octanoic acid (**15**) in CDCl_3 at 298 K.




Figure S118. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-methylformamide (**16**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S119. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-methylformamide (**16**) in CDCl_3 at 298 K.




Figure S120. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N,N*-dimethylformamide (**17**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S121. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N,N*-dimethylformamide (**17**) in CDCl_3 at 298 K.




Figure S122. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-ethylformamide (**18**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S123. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-ethylformamide (**18**) in CDCl_3 at 298 K.




Figure S124. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-octylformamide (**19**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S125. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-octylformamide (**19**) in CDCl_3 at 298 K.




Figure S126. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-methylacetamide (**20**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S127. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-methylacetamide (**20**) in CDCl_3 at 298 K.




Figure S128. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-ethylacetamide (**21**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S129. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-ethylacetamide (**21**) in CDCl_3 at 298 K.




Figure S130. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-propylacetamide (**22**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S131. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-propylacetamide (**22**) in CDCl_3 at 298 K.




Figure S132. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-butylacetamide (**23**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S133. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-methylpropionamide (**24**) in CDCl_3 at 298 K.




Figure S134. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-methylpropionamide (**24**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S135. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-methylpropionamide (**24**) in CDCl_3 at 298 K.




Figure S136. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-butylpentanamide (**25**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S137. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-butylpentanamide (**25**) in CDCl_3 at 298 K.




Figure S138. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-methyl pyrrolidone (**26**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S139. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-methyl pyrrolidone (**26**) in CDCl_3 at 298 K.




Figure S140. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and THF (**27**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S141. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and pyrole (**28**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S142. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and imidazole (**29**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S143. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with imidazole (**29**) in CDCl_3 at 298 K.




Figure S144. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and oxazole (**30**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S145. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with oxazole (**30**) in CDCl_3 at 298 K.




Figure S146. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and thiazole (**31**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S147. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with thiazole (**31**) in CDCl_3 at 298 K.




Figure S148. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and 4-methylthiazole (**32**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S149. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with 4-methylthiazole (**32**) in CDCl_3 at 298 K.




Figure S150. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and 3,5-dimethylisoxazole (**33**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S151. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with 3,5-dimethylisoxazole (**33**) in CDCl_3 at 298 K.




Figure S152. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and 1-butylimidazole (**34**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S153. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with 1-butylimidazole (**34**) in CDCl_3 at 298 K.




Figure S154. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and dimethylsulfoxide (**35**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S155. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_α) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with dimethylsulfoxide (**35**) in CDCl_3 at 298 K.




Figure S156. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and 1-nitropropane (**36**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S157. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with 1-nitropropane (**36**) in CDCl_3 at 298 K.




Figure S158. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and acetonitrile (**37**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S159. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with acetonitrile (**37**) in CDCl_3 at 298 K.




Figure S160. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and of 2-butyloxirane (**38**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S161. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with 2-butyloxirane (**38**) in CDCl_3 at 298 K.




Figure S162. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-(3-hydroxypropyl)acetamide (**39**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S163. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-(3-hydroxypropyl)acetamide (**39**) in CDCl_3 at 298 K.




Figure S164. Partial ^1H NMR spectra (400 MHz, CDCl_3 , 298 K) of a mixture of **[P4-(OH)BPO]** (10.0 mM) and *N*-(3-hydroxypropyl)formamide (**40**) at the concentrations of 0, 2.0, 6.0, 10.0, 20.0, 40.0, 80.0, 120.0, 160.0, 320.0, and 640.0 mM (from bottom to top).




Figure S165. The nonlinear curve fitting of NMR titration ($\Delta\delta$ of H_a) for the complexation of **[P4-(OH)BPO]** (10.0 mM) with *N*-(3-hydroxypropyl)formamide (**40**) in CDCl_3 at 298 K.

2D NOESY Spectra




Figure S166. Partial 2D NOESY spectrum (400 MHz, CDCl_3 , 298 K) of the mixture of **[P4-(OH)BPO]** (40 mM) and *n*-butylamine (**1**) (160 mM).




Figure S167. Partial 2D NOESY spectrum (400 MHz, CDCl_3 , 298 K) of the mixture of **[P4-(OH)BPO]** (40 mM) and *n*-butanol (**4**) (160 mM).




Figure S168. Partial 2D NOESY spectrum (400 MHz, CDCl_3 , 298 K) of the mixture of **[P4-(OH)BPO]** (40 mM) and *n*-butyraldehyde (**7**) (160 mM).




Figure S169. Partial 2D NOESY spectrum (400 MHz, CDCl_3 , 298 K) of the mixture of **[P4-(OH)BPO]** (40 mM) and methyl butyrate (**10**) (160 mM).




Figure S170. Partial 2D NOESY spectrum (400 MHz, CDCl_3 , 298 K) of the mixture of **[P4-(OH)BPO]** (40 mM) and *n*-butanoic acid (**13**) (160 mM).




Figure S171. Partial 2D NOESY spectrum (400 MHz, CDCl_3 , 298 K) of the mixture of **[P4-(OH)BPO]** (40 mM) and *N*-butylpentanamide (**25**) (160 mM).




Figure S172. Partial 2D NOESY spectrum (400 MHz, CDCl_3 , 298 K) of the mixture of **[P4-(OH)BPO]** (40 mM) and imidazole (**29**) (160 mM).




Figure S173. Partial 2D NOESY spectrum (400 MHz, CDCl_3 , 298 K) of the mixture of **[P4-(OH)BPO]** (40 mM) and 2-butyloxirane (**39**) (160 mM).




Figure S174. Partial 2D NOESY spectrum (400 MHz, CDCl_3 , 298 K) of the mixture of **[P4-(OH)BPO]** (40 mM) and *N*-(3-hydroxypropyl)acetamide (**40**) (160 mM).






Figure S175. Partial 2D NOESY spectrum (400 MHz, CDCl_3 , 298 K) of the mixture of **[P4-(OH)BPO]** (40 mM) and hexane (160 mM).


Single-Crystal X-ray Crystallography




Crystallographic Data of acetone-*endo*-[P4-BPO(1-OH)]: $C_{52}H_{56}O_{11}$ ($M=856.96$ g/mol): triclinic, space group P-1 (no. 2), $a = 12.6595(3)$ Å, $b = 16.8962(5)$ Å, $c = 23.3017(7)$ Å, $\alpha = 109.239(3)^\circ$, $\beta = 91.141(2)^\circ$, $\gamma = 99.679(2)^\circ$, $V = 4623.6(2)$ Å³, $Z = 4$, $T = 169.99(10)$ K, $\mu(\text{Cu K}\alpha) = 0.697$ mm⁻¹, $D_{\text{calc}} = 1.231$ g/cm³, 51235 reflections measured ($7.106^\circ \leq 2\Theta \leq 134.158^\circ$), 16409 unique ($R_{\text{int}} = 0.0476$, $R_{\text{sigma}} = 0.0494$) which were used in all calculations. The final R_1 was 0.0588 ($I > 2\sigma(I)$) and wR_2 was 0.1668 (all data).




Crystallographic Data of 9c_{endo}-[P4-(OH)BPO]: [C₅₇ H₆₆ O₁₁]; $M_r = 927.09$; T = 100.0 K; monoclinic; space group P2₁/n; $a = 12.2551(4)$; $b = 35.3374(12)$; $c = 12.3763(5)$ Å; $\alpha = 90^\circ$; $\beta = 112.092(4)$; $\gamma = 90^\circ$; $V = 4966.2(3)$ Å³; Z = 4; $\rho_{\text{calcd}} = 1.240$ g/cm³; $\mu = 0.686$ mm⁻¹; reflections collected 33633; unique reflections 9836; data/restraints/parameters 9836/0/623; GOF on F_2 1.077; R_{int} for independent data 0.0894; final $R_I = 0.1311$, $wR_2 = 0.3371$; R indices (all data) $R_I = 0.1473$, $wR_2 = 0.3453$; largest diff. peak and hole: 0.63 and -0.38 eÅ⁻³.




Crystallographic Data of 13c_{endo}-[P4-BPO(1-OH)]: [C₁₆₃ H₁₈₄ NO₃₉]; *Mr* = 2767.09; T = 100.01(10) K; triclinic; space group P-1; *a* = 13.1627(4); *b* = 23.5857(5); *c* = 25.1617(8) Å; α = 92.714(2); β = 94.925(3); γ = 91.465(2); *V* = 7770.5(4) Å³; *Z* = 2; ρ_{calcd} = 1.183 g/cm³; μ = 0.685 mm⁻¹; reflections collected 57624; unique reflections 30492; data/restraints/parameters 30492/0/1857; *GOF* on *F*² 1.038; *R*_{int} for independent data 0.0570; final *R*₁ = 0.0784, *wR*₂ = 0.2193; *R* indices (all data) *R*₁ = 0.1187, *wR*₂ = 0.2546; largest diff. peak and hole: 0.48 and -0.70 eÅ⁻³.




Crystallographic Data of 17c_{endo}-[P4-BPO(1-OH)]: C₅₂H₅₇NO₁₁ ($M=871.98$ g/mol): monoclinic, space group P2₁/c (no. 14), $a = 14.722(2)$ Å, $b = 13.987(2)$ Å, $c = 22.898(3)$ Å, $\beta = 96.609(4)^\circ$, $V = 4683.6(12)$ Å³, $Z = 4$, $T = 150.01$ K, $\mu(\text{MoK}\alpha) = 0.086$ mm⁻¹, $D_{\text{calc}} = 1.237$ g/cm³, 45103 reflections measured ($4.276^\circ \leq 2\Theta \leq 41.846^\circ$), 4766 unique ($R_{\text{int}} = 0.1087$, $R_{\text{sigma}} = 0.0523$) which were used in all calculations. The final R_1 was 0.0683 ($I > 2\sigma(I)$) and wR_2 was 0.2285 (all data).




Crystallographic Data of 21c *endo*-[P4-BPO(1-OH)]:
 $C_{59.125}H_{53.75}O_{5.375}N_{5.375}$ ($M=925.57$ g/mol): orthorhombic, space group $Pca2_1$ (no. 29), $a = 22.9741(4)$ Å, $b = 19.0211(6)$ Å, $c = 23.0178(5)$ Å, $V = 10058.6(4)$ Å³, $Z = 8$, $T = 100.00(13)$ K, $\mu(\text{CuK}\alpha) = 0.629$ mm⁻¹, $D_{\text{calc}} = 1.222$ g/cm³, 68268 reflections measured ($4.646^\circ \leq 2\Theta \leq 134.158^\circ$), 17154 unique ($R_{\text{int}} = 0.0768$, $R_{\text{sigma}} = 0.0560$) which were used in all calculations. The final R_1 was 0.2440 ($I > 2\sigma(I)$) and wR_2 was 0.5872 (all data).




Crystallographic Data of 24c_{endo}-[P4-BPO(1-OH)]: [C₅₃H₅₉N O₁₁]; $M_r = 886.01$; T = 100.01(13) K; triclinic; space group P-1; $a = 12.6244(4)$; $b = 17.1050(5)$; $c = 23.3091(7)$ Å; $\alpha = 109.895(3)$; $\beta = 91.763(3)$; $\gamma = 98.274(3)$; $V = 4966.5(3)$ Å³; Z = 4; $\rho_{\text{calcd}} = 1.261$ g/cm³; $\mu = 0.713$ mm⁻¹; reflections collected 34743; unique reflections 18214; data/restraints/parameters 18214/2/1193; GOF on F_2 1.006; R_{int} for independent data 0.0680; final $R_I = 0.0977$, $wR_2 = 0.2449$; R indices (all data) $R_I = 0.1359$, $wR_2 = 0.2744$; largest diff. peak and hole: 0.84 and -0.55 eÅ⁻³.




Crystallographic Data of 25c_{endo}-[P4-BPO(1-OH)]: for $C_{57.5}H_{68}NO_{11}$ ($M = 949.12$ g/mol): monoclinic, space group $P2_1/c$ (no. 14), $a = 23.0837(2)$ Å, $b = 19.0807(3)$ Å, $c = 23.0142(3)$ Å, $\beta = 90.2020(10)^\circ$, $V = 10136.6(2)$ Å³, $Z = 8$, $T = 149.99(10)$ K, $\mu(\text{Cu K}\alpha) = 0.689$ mm⁻¹, $D_{\text{calc}} = 1.244$ g/cm³, 19523 reflections measured ($3.828^\circ \leq 2\Theta \leq 147.862^\circ$), 19523 unique ($R_{\text{int}} = ?$, $R_{\text{sigma}} = 0.0341$) which were used in all calculations. The final R_1 was 0.1125 ($I > 2\sigma(I)$) and wR_2 was 0.3108 (all data).



Crystallographic Data of 31c*endo*-[P4-BPO(1-OH)]: $C_{52}H_{53}NO_{10}S$ ($M=884.01$ g/mol): monoclinic, space group $P2_1/c$ (no. 14), $a = 11.8319(2)$ Å, $b = 41.9003(5)$ Å, $c = 11.0969(2)$ Å, $\beta = 112.302(2)^\circ$, $V = 5089.88(16)$ Å 3 , $Z = 4$, $T = 100.01(10)$ K, $\mu(\text{CuK}\alpha) = 1.013$ mm $^{-1}$, $D_{\text{calc}} = 1.154$ g/cm 3 , 54175 reflections measured ($8.348^\circ \leq 2\Theta \leq 134.16^\circ$), 9038 unique ($R_{\text{int}} = 0.0438$, $R_{\text{sigma}} = 0.0284$) which were used in all calculations. The final R_1 was 0.0514 ($I > 2\sigma(I)$) and wR_2 was 0.1363 (all data).



Crystallographic Data of 36c*endo*-[P4-BPO(1-OH)]: $C_{51}H_{56}O_{11}S$ ($M=877.01$ g/mol): triclinic, space group P-1 (no. 2), $a = 12.5943(3)$ Å, $b = 16.8101(4)$ Å, $c = 23.4261(5)$ Å, $\alpha = 109.411(2)^\circ$, $\beta = 91.212(2)^\circ$, $\gamma = 99.439(2)^\circ$, $V = 4599.05(19)$ Å³, $Z = 4$, $T = 99.99(11)$ K, $\mu(CuK\alpha) = 1.125$ mm⁻¹, $D_{\text{calc}} = 1.267$ g/cm³, 53526 reflections measured ($7.138^\circ \leq 2\Theta \leq 134.148^\circ$), 16323 unique ($R_{\text{int}} = 0.0918$, $R_{\text{sigma}} = 0.0801$) which were used in all calculations. The final R_1 was 0.0682 ($I > 2\sigma(I)$) and wR_2 was 0.1947 (all data).




Crystallographic Data of hexane-2,2,6,6-tetra(1-OH)-[P4-BPO(1-OH)]: $C_{55}H_{63}O_{10}$ ($M = 884.05$ g/mol): triclinic, space group P-1 (no. 2), $a = 10.4720(14)$ Å, $b = 12.1028(17)$ Å, $c = 21.674(3)$ Å, $\alpha = 75.542(12)^\circ$, $\beta = 84.585(11)^\circ$, $\gamma = 70.595(12)^\circ$, $V = 2508.7(6)$ Å³, $Z = 2$, $T = 100.0(4)$ K, $\mu(\text{Cu K}\alpha) = 0.640$ mm⁻¹, $D_{\text{calc}} = 1.170$ g/cm³, 14523 reflections measured ($4.21^\circ \leq 2\Theta \leq 148.078^\circ$), 8617 unique ($R_{\text{int}} = 0.1483$, $R_{\text{sigma}} = 0.1624$) which were used in all calculations. The final R_1 was 0.1489 ($I > 2\sigma(I)$) and wR_2 was 0.4352 (all data).

Calculation of Mulliken Charges


The configurations of amides were optimized and Mulliken charges of atoms were calculated using Gaussian 09 at PM6D3 level.

Calculated Mulliken charges for the atoms in **21**




label	atom	Mulliken charge
1	C	-0.617364
2	C	0.640383
3	N	-0.537076
4	O	-0.558618
5	C	-0.031049
6	C	-0.505309
7	H	0.203227
8	H	0.186879
9	H	0.186885
10	H	0.269917
11	H	0.139389
12	H	0.139417
13	H	0.165025
14	H	0.159150
15	H	0.159142

Calculated Mulliken charges for the atoms in **24**



label	atom	Mulliken charge
1	C	-0.374248
2	C	0.602575
3	C	-0.419733
4	N	-0.509102
5	O	-0.543106
6	C	-0.266655
7	H	0.163304
8	H	0.163281
9	H	0.143461
10	H	0.161465
11	H	0.161484
12	H	0.264243
13	H	0.139101
14	H	0.156961
15	H	0.156970

Calculated Mulliken charges for the atoms in **25**



label	atom	Mulliken charge	label	atom	Mulliken charge
1	C	0.601771	16	H	0.144657
2	N	-0.518556	17	H	0.142606
3	C	-0.417205	18	H	0.142601
4	O	-0.572379	19	H	0.131052
5	C	-0.075983	20	H	0.131051
6	C	-0.308098	21	H	0.133263
7	C	-0.210534	22	H	0.133250
8	C	-0.239671	23	H	0.131007
9	C	-0.221022	24	H	0.131008
10	C	-0.465088	25	H	0.149009
11	C	-0.464434	26	H	0.148024
12	H	0.269452	27	H	0.148022
13	H	0.183265	28	H	0.148627
14	H	0.183244	29	H	0.148203
15	H	0.144655	30	H	0.148202

References:

- S1. Xie, C.-D. et al. Synthesis of pillar[n]arene[5–n]quinines via partial oxidation of pillar[5]arene. *Chin. J. Chem.* **33**, 379–383 (2015).
- S2. Ulatowski, F., Dąbrowa, K., Bałakier, T., Jurczak, J. Recognizing the limited applicability of Job plots in studying host–guest interactions in supramolecular chemistry
- S3. Thordarson, P. Determining association constants from titration experiments in supramolecular chemistry. *Chem. Soc. Rev.* **40**, 1305–1323 (2011).
- S4. Frisch M. J. *et al.* *Gaussian 16 Revision A 03* (Gaussian Inc., Wallingford, 2016).
- S5. Lu, T. & Chen, F. Multiwfn: a multifunctional wavefunction analyzer. *J. Comput. Chem.* **33**, 580–592 (2012)
- S6. Smulders, M. M. J., Zarra, S. & Nitschke, J. R. Quantitative understanding of guest binding enables the design of complex host–guest behavior. *J. Am. Chem. Soc.* **135**, 7039–7046 (2013).
- S7. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **31**, 455–461 (2010)